SAMPATRILAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H40N4O9S
Molecular Weight	584.682
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(O)=O)C(O)=O

InChI

InChIKey=LPUDGHQMOAHMMF-JBACZVJFSA-N

InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H40N4O9S
Molecular Weight	584.682
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9535199 | https://adisinsight.springer.com/drugs/800005729 | https://www.ncbi.nlm.nih.gov/pubmed/21853869

Sampatrilat (also known as UK 81252) was developed as a dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This drug was studied for the treatment of hypertension and congestive heart failure.

Approval Year

PubMed

Title	Date	PubMed
Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.	1996 Nov	8922744
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.	1998 Jan	9535199
Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.	2003 Apr	12649357
Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration.	2004 Jan 23	15144729
The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.	2009	21853869

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:23:09 UTC 2023` Edited by `admin` on `Sat Dec 16 16:23:09 UTC 2023`
Record UNII	V7O29949TG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAMPATRILAT

Official Name

English

Sampatrilat [WHO-DD]

Common Name

English

sampatrilat [INN]

Common Name

English

N-((1-((S)-3-((S)-6-AMINO-2-METHANESULFONAMIDOHEXANAMIDO)-2-CARBOXYPROPYL)CYCLOPENTYL)CARBONYL)-L-TYROSINE

Systematic Name

English

UK-81,252

Code

English

L-TYROSINE, N2-(METHYLSULFONYL)-L-LYSYL-1-((2S)-3-AMINO-2-CARBOXYPROPYL)CYCLOPENTANECARBONYL-

Systematic Name

English

SAMPATRILAT [MI]

Common Name

English

UK-81252

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C247